# BASSER CENTER for brca

## 6<sup>TH</sup> ANNUAL SCIENTIFIC SYMPOSIUM A CME/CNE - Certified Conference

## BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer

Keynote Speaker and Basser Global Prize Awardee: Professor Ashok Venkitaraman, MBBS, PhD

## TUESDAY, MAY 22, 2018 WEDNESDAY, MAY 23, 2018

Smilow Center for Translational Research Auditorium/Commons

(enter through Perelman Center for Advanced Medicine)



## **Program Overview**

This symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned *BRCA1/2* researchers. This symposium will provide new information on the basic biology of known cancer susceptibility genes. In addition, progress in cancer screening and prevention as well as ongoing work in targeted therapy for *BRCA1/2* mutation carriers will be discussed through a series of lectures and panel discussions. Attendees will have the opportunity to network with colleagues working in the field.

## PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:

- Discuss new research on the basic biology of *BRCA1* and *BRCA2* and other homologous repair deficiency genes.
- Describe the current clinical management strategies for individuals with genetic risk of breast, ovarian and pancreatic cancer.
- Review new approaches to screening and prevention of hereditary breast and ovarian cancer.
- Discuss new advances in cancer treatment for BRCA1/2 mutation carriers.

## WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, ob-gyn, genetic counselors, primary care physicians and nurses/nurse practitioners who are interested in the genetics of *BRCA1/2* related cancers.



## KEYNOTE SPEAKER AND BASSER GLOBAL PRIZE AWARDEE Ashok Venkitaraman, MBBS, PhD University of Cambridge

Efforts to identify new opportunities for early, non-invasive interventions for BRCA carriers is a high priority in the field. Professor Venkitaraman is the Ursula Zoellner Professor of Cancer Research

and Director of the Medical Research Council Cancer Unit at the University of Cambridge. Professor Venkitaraman's laboratory has been instrumental in showing how mutations in *BRCA2* incite genomic instability, accelerating cancer development. His current research focuses on deeper understanding of how cancer is initiated in patients with *BRCA2* mutations and has recently uncovered how certain chemicals in the environment or within an individual can trigger genome instability. His team is exploiting this discovery to devise future approaches for cancer prevention and treatment.



## SYMPOSIUM CHAIR

## Susan M. Domchek, MD

Executive Director, Basser Center for BRCA Director, Mariann and Robert MacDonald Cancer Risk Evaluation Center

Susan Domchek is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as

Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Program. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for patients with genetic risk factors. An elected member of the American Society of Clinical Investigation, Dr. Domchek is also a member of the American Society of Clinical Oncology. A significant contributor to the oncology literature, she has authored/co-authored more than 250 articles appearing in scholarly journals including the *New England Journal of Medicine*, the *Journal of the American Medical Association* and the *Journal of Clinical Oncology*. Dr. Domchek also serves on a number of editorial review boards, including the Journal of Clinical Oncology, as well as on the Scientific Advisory Board for the Breast Cancer Research Foundation.

#### SYMPOSIUM CO-ORGANIZERS

#### Ronald Drapkin, MD, PhD

Associate Professor of Pathology in Obstetrics & Gynecology Director, Ovarian Cancer Research Center Director of Gynecologic Cancer Research, Basser Center for BRCA

## Dana Farengo-Clark, MS, MS, LCGC

Senior Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

## Roger Greenberg, MD, PhD

Professor of Cancer Biology Investigator, Abramson Family Cancer Research Institute Director of Basic Science, Basser Center for BRCA

## Robin Herzog, MSN, CRNP

Nurse Practitioner Department of Hematology Oncology Abramson Cancer Center University of Pennsylvania

## Katherine Nathanson, MD

Professor of Medicine Deputy Director, Abramson Cancer Center Director of Genetics, Basser Center for BRCA

## PENN MEDICINE FACULTY

### C. Neill Epperson, MD

Professor of Obstetrics and Gynecology Professor of Psychiatry Director, Penn Center for Women's Behavioral Wellness

## Jessica Long, MS, LCGC

Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

## Danielle McKenna, MS, LCGC

Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

Mark Morgan, MD Professor of Gynecologic Oncology Chief, Division of Gynecologic Oncology

Arjun Raj, PhD Associate Professor Department of Bioengineering

**Fiona Simpkins, MD** Assistant Professor Department of Medicine Obstetrics and Gynecology

## **GUEST SPEAKERS**

## Georgia Chenevix–Trench, PhD, FAA, FAHMS

Senior Scientist Head, Department of Genetics and Computational

Biology

QIMR Berghofer Medical Research Institute Queensland, Australia

## **GUEST SPEAKERS CONTINUED**

#### Kathleen Cho, MD

Peter A. Ward Professor of Pathology Vice-Chair for Academic Affairs Department of Pathology University of Michigan Medical School

## Fergus Couch, PhD

Zbigniew and Anna M. Scheller Professor of Medical Research Chair, Division of Experimental Pathology Department of Laboratory Medicine and Pathology Mayo Clinic

## Tony Huang, PhD

Associate Professor Department of Biochemistry and Molecular Pharmacology NYU School of Medicine

#### Allison Kurian, MD, MSc

Associate Professor of Medicine (Oncology) and of Health Research and Policy Stanford University Medical Center

## Lisa Madlensky, PhD, CGC

Professor, Division of Medical Genetics Program Director & Genetic Counselor, Family Cancer Genetics Program Moores Cancer Center University of California

## Ursula Matulonis, MD

Professor of Medicine, Harvard Medical School Director, Gynecologic Oncology Dana Farber Cancer Institute

### Elaine Ostrander, PhD

Chief & Distinguished Investigator Cancer Genetics & Comparative Genomics Branch National Human Genome Research Institute National Institutes of Health

## Jeffery Parvin, MD, PhD

Louis Levy Professor for Cancer Associate Dean of Graduate Studies, Co-Director of the Biomedical Sciences Program Department of Biomedical Informatics The Ohio State University

#### **Richard Pomerantz, PhD**

Assistant Professor, Medical Genetics & Molecular Biochemistry Assistant Professor, Fels Institute for Cancer Research & Molecular Biology Lewis Katz School of Medicine at Temple University

#### Yves Pommier, MD, PhD

Chief, Developmental Therapeutics Branch Head, Molecular Pharmacology Group Center for Cancer Research National Cancer Institute

#### Mark Robson, MD

Chief, Breast Medicine Service Clinic Director, Clinical Genetics Service Memorial Sloan Kettering Cancer Center

#### Gerburg Wulf, MD, PhD

Associate Professor of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center

# $6^{\text{TH}}$ annual scientific symposium AGENDA

## TUESDAY, MAY 22, 2018

## Smilow Center for Translational Research | Auditorium/Commons

- 7:45-8:30 Registration
- 8:30-8:40 Welcome

## **Morning Session**

- 8:40-9:05 Rare cell biology and response to targeted therapy in cancer Arjun Raj, PhD
- 9:05-9:30 Optimizing PARP inhibitors for ovarian cancer... the lab to the clinic Fiona Simpkins, MD
- 9:30-9:55 Beyond single agent PARP inhibitors: PARP inhibitor combination strategies Ursula Matulonis, MD
- 9:55-10:25 BREAK
- 10:25-10:50 Mouse models of "ovarian" cancer: progress, problems, and potential platforms for testing prevention strategies Kathleen Cho, MD
- 10:50-11:15 Tumor metabolism in *BRCA*-related breast cancer implications for treatment Gerburg Wulf, MD, PhD
- 11:15-11:40 New functions and inhibitors of polymerase theta Richard Pomerantz, PhD
- 11:40-1:30 LUNCH

# $6^{\text{TH}}$ annual scientific symposium AGENDA

## TUESDAY, MAY 22, 2018

## Smilow Center for Translational Research | Auditorium/Commons

## **Afternoon Session**

1:30-1:55	Understanding how replication stress influences replication origin firing efficiency by genome-wide analyses Tony Huang, PhD
1:55-2:20	PARP inhibitors and precision medicine Yves Pommier, MD, PhD
2:20-2:45	How DNA damage activates immune responses to cancer Roger Greenberg, MD, PhD
2:45-3:00	BREAK
3:00-4:30	Global Prize Presentation and Keynote How mutations affecting the <i>BRCA2</i> gene cause cancer susceptibility <b>Professor Ashok Venkitaraman</b>
4:30-6:00	Poster Reception
5:30-6:30	Breakthroughs and Discoveries Panel moderated by Susan Domchek and featuring Ashok Venkitaraman, Ursula Matulonis and Georgia Chenevix–Trench. <i>This lay session is open to the public and will begin promptly at 5:30</i> .

# $6^{\text{TH}}$ annual scientific symposium AGENDA

## WEDNESDAY, MAY 23, 2018

## Smilow Center for Translational Research | Auditorium/Commons

- 7:45-8:30 Registration
- 8:30-8:40 Welcome

## Morning Session

8:40-9:05	A multiplexed homology-directed DNA repair assay to assess the effects of variants in <i>BRCA1</i> Jeffrey Parvin, MD, PhD
9:05-9:30	Role of <i>BRCA2</i> in susceptibility to prostate cancer Elaine Ostrander, PhD
9:30-9:55	Contributions of non- <i>BRCA</i> predisposition genes to hereditary cancer <b>Fergus Couch</b> , PhD
9:55-10:25	BREAK
10:25-10:50	Genetic risk assessment and risk reduction of women's cancers: Progress and challenges Allison Kurian, MD, MSc
10:50-11:15	Clinical application of polygenic risk scores: ready or not, here it comes Mark Robson, MD
11:15-11:40	Beyond GWAS: moving from SNP to gene and biological function Georgia Chenevix–Trench, PhD
11:40-12:05	Cancer genetic counseling in transgender patients: unique considerations Danielle McKenna, LCGC
12:05-1:30	LUNCH

# $6^{\text{TH}}$ annual scientific symposium AGENDA

## WEDNESDAY, MAY 23, 2018

## Smilow Center for Translational Research | Auditorium/Commons

## **Afternoon Session**

1:30-1:55	Risk factors for executive function difficulties after RRSO C. Neill Epperson, MD
1:55-2:20	Ovarian cancer prevention and treatment for women with homologous recombination defects Mark Morgan, MD
2:20-2:45	Cancer genetic testing at the end of life: challenges, opportunities, and legacies Lisa Madlensky, PhD, CGC
2:55-4:00	Panel Discussion: Cancer Genetics Case Review Moderated by Susan Domchek, MD and featuring Allison Kurian, Mark Robson and Basser Genetic Counselor Jessica Long

4:00-4:15 Wrap up and Evaluations

## **Registration Information**

## REGISTER ONLINE

This conference is **FREE** but we strongly recommend registration, as space is limited.

#### ACCREDITATION AND DESIGNATION OF CREDIT

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. In support of improving patient care, Penn Medicine is jointly accredited by the Acrreditation Council of Continuing Medical Education (ACCME), the Accreditation Council fo Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team. Total physician and nurse credits 10.25.

**PHYSICIANS** Penn Medicine designates this live activity for a maximum of 13 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES The program will award 13 contact hours.

**GENETIC COUNSELORS** This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

#### DISCLOSURES

Penn Medicine, Office of Continuing Medical and Interprofessional Education, adheres to the ACCME Standards for Commercial Support. Faculty disclosure information will be made available at the conference. Faculty members are also expected to disclose to participants any discussion of off-label and/or investigational use of pharmaceutical products or devices within their presentations.

#### **CANCELLATION POLICY**

The University reserves the right to cancel or postpone any activity due to unforeseen circumstances. In the event of cancellation or postponement, the University will not be responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, or travel agencies.

#### SERVICES FOR THE DISABLED

If special arrangements are required for an individual with a disability to attend this meeting, please contact basserinfo@uphs.upenn.edu by April 27, 2018.

#### SPECIAL REQUESTS


If special requests for food or other logistics are required, contact basserinfo@uphs.upenn.edu by April 27, 2018.

#### NONDISCRIMINATION STATEMENT

The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East, Suite 228, Philadelphia, PA 19104-6106 or 215.898.6993 (Voice) or 215.898.7803 (TDD).

## Visiting Information

## PENN MEDICINE CAMPUS MAP



## HOTEL

A block of rooms has been reserved at the **Sheraton Philadelphia University City Hotel** at a special group rate of \$194 per night.

Rooms must be reserved by Sunday, April 22, 2018 to take advantage of the group rate.

**RESERVE YOUR ROOM** 

For more information, contact Basserinfo@uphs.upenn.edu or call 215.662.4348

# Visiting Information

## PARKING


Parking will not be available on the medical campus, but public self-pay parking lots available in the University City vicinity can be found at:

- Drexel University Parking Lot 34th and Market Streets
- University of Pennylvania Parking Lot 34th and Chestnut Streets
- University of Pennsylvania Parking Lot 38th and Walnut Streets

For more information, visit <a href="http://cms.business-services.upenn.edu/parking/">http://cms.business-services.upenn.edu/parking/</a>

## PUBLIC TRANSPORTATION

The SEPTA University City train station is within walking distance of the medical campus. For more information, visit <u>www.septa.org</u>.



For more information, contact Basserinfo@uphs.upenn.edu or call 215.662.4348

The Basser Center for BRCA is the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA mutations, the Basser Center's unique model provides funding for collaborative research, education and outreach programs around the world.

WE TAKE CANCER PERSONALLY.



